BioCentury
ARTICLE | Company News

Adocia, Lilly deal

February 3, 2017 12:41 AM UTC

Eli Lilly terminated a 2014 deal and returned rights to Adocia's BioChaperone Lispro to treat Type I and Type II diabetes. Lilly had paid $50 million up front for exclusive, worldwide rights to the ultra-fast-acting formulation of insulin lispro using BioChaperone polymer technology. Adocia said it will continue preparations for Phase III testing of BioChaperone Lispro while seeking a new partner. Lilly said the pharma has chosen to further develop another, unnamed ultra-rapid insulin program, which has completed Phase I testing to treat Type I and Type II diabetes. Lilly plans to submit data for the program for presentation in July at the American Diabetes Association Scientific Sessions meeting in San Diego. ...

BCIQ Company Profiles

Adocia S.A.

Eli Lilly and Co.

BCIQ Target Profiles

Insulin receptor (INSR)